The clocks have changed and summer is long gone so it's natural to want to hibernate or focus on the holidays to ease the pain of the approaching winter weather. However, fall is the perfect season to get outside, take in nature or learn something new! Plus, you won't feel so guilty come Thanksgiving dinner if you have had an active November! Here are some great ideas to get active and keep working out this fall!
Fall can be a treat for the senses with the crisp air and the crunch of leaves underfoot; walking, hiking and cycling are all great in fall, so take the opportunity to discover park trails and take in some new scenery. In places where snow falls early, try cross country skiing or snowshoeing, or, if you live near the beach, get out and play volleyball, throw the Frisbee around, or play a vigorous game of fetch with your dog – being beside the ocean can be really invigorating in the colder months and it's much less crowded. If you live near a lake, try kayaking or canoeing for an excellent whole-body workout and a great change of pace. And remember, it doesn't have to seem like exercise to be a great workout; raking leaves or doing some outdoor yard work is a great way to get the heart pumping, and it's great for burning calories.
Everyone joins the gym in January, so this month is a great time to get there before everyone else and feel like an expert by the time the New Year's resolutions roll around. Many gyms also have offers at this time of year as these months are usually slow for business since everyone is thinking about the holidays and puts off getting fit until January. You'll benefit from all the benefits that exercise gives you, and what's more, fall is the perfect time to gain new physical skills, as if you learn something new now, by next summer, you'll have mastered the skill -- and you'll burn more calories doing it, just in time for swimsuit season.
Don't dread the darkness; the best way to enjoy fall is to exercise outdoors, but it's getting darker earlier, and staying dark later in the morning, so be smart and safe. If you're walking or running outdoors, wear a reflective vest and carry a flashlight. When cycling, fix a light to your helmet or bike, and if possible, use trails or a local school track to avoid vehicle traffic. Try to work out at the same time every day, so drivers get used to seeing you.
Many people get geared up for fall premieres of their favorite TV shows, but if you're going to sit down and watch hours of TV, then this is the ideal time to also get moving! If you can record your favorite show, do that and go for a walk after dinner, then you don't have to sit through the commercials and you'll feel more energized after some time in the fresh air. If you want to watch live or the weather's bad, you probably have close to 20 minutes worth of commercial interruption during a one-hour show, so use this time to do push-ups, sit-ups, lunges, tricep dips or lift weights. In addition, you'll keep yourself occupied and avoid mindless snacking in front of the TV.
When exercising outside, layer your clothing. These days, there's no lack of great weather gear; the best out there is clothing with wicking, often called 'DriFit'. This fabric takes moisture away from your skin so you're not exercising with wet fabric hanging on you and getting cold. Your inner layer should be a moisture-wicking fabric, the second layer should be a warmth layer, and the third layer should be a protective layer, like a windbreaker or rain slicker, depending on the weather. Put on a pair of sunglasses with UV protection to block out the low autumn sun and you're good to go!
To ensure that your work-out program is going to be successful, you need to make sure it has all of "the three Cs": commitment, convenience, and consistency. First, exercise takes commitment; this time of year is busy with work, school, holidays and all the other things that we use to excuse ourselves from exercise so it's the perfect time to test if you have what it takes to go the distance. Planning is the key to weight loss success; you have to plan time for exercise just like you would plan to do anything. Put it on the calendar, because later always turns to never. Convenience means choosing a gym that's close by, an activity you can do at home, or a time when you're not likely to be interrupted. You know your routine and whether you can fit in your plan to work out, so if it's not convenient, change it. Lastly, there's consistency; ten minutes a day is better than an hour a month, so make sure it's something that you can do regularly, even if only in short bursts.
Here you have lots of good ways to ensure that you don't slack off this fall, but if you feel you need some extra energy then the weight loss supplement Phen Caps are perfect for you. Phen Caps will boost your energy levels and suppress your appetite, ensuring that this season will get your weight loss journey on the track to success!


National security must reflect the resolve of South Africans, as individuals and as a nation, to live as equals, to live in peace and harmony, to be free from fear and want and to seek a better life.
The resolve to live in peace and harmony precludes any South African citizen from participating in armed conflict, nationally or internationally, except as provided for in terms of the Constitution or national legislation.
National security must be pursued in compliance with the law, including international law.
National security is subject to the authority of Parliament and the national executive.
further, in a partisan manner, any interest of a political party.
in fulfilment of an international obligation.
the period for which the force is expected to be employed.
202. (1) The President as head of the national executive is Commander-in- Chief of the defence force, and must appoint the Military Command of the defence force.
to liaise with the Cabinet member responsible for policing with respect to crime and policing in the province.
allocated to it in the national policing policy.
must make recommendations to the Cabinet member responsible for policing.
(8) A committee composed of the Cabinet member and the members of the Executive Councils responsible for policing must be established to ensure effective co-ordination of the police service and effective co-operation among the spheres of government.
subject to the power of the National Commissioner to exercise control over and manage the police service in terms of subsection (2).
civilian monitoring of the activities of those services by an inspector appointed by the President, as head of the national executive, and approved by a resolution adopted by the National Assembly with a supporting vote of at least two thirds of its members.


Saint Xavier University (SXU) recently hosted a press conference for the Illinois Board of Higher Education (IBHE) to announce a new partnership between IBHE, the Council for Adult and Experiential Learning, and four Illinois regional communities that were awarded a $238,100 grant aimed at aligning higher education programs with workforce needs identified by in-demand industries. SXU President Christine Wiseman was quoted in the Friday, Sept. 30 issue of the Daily Southtown. In the article, President Wiseman expressed hope that the south Chicago region would pursue the same funding and study program in the near future.


Igor Zaks, President and CEO of TenzorAI, presents his personal view of the basics of artificial intelligence.
3. AI – where it is today and where it should be used.
CTMfile take: There are many views about how artificial intelligence/machine learning really works. This is Igor's view and why corporate treasury is ripe for AI.
AI expanding in cash and treasury management but WHO is checking the results?


Executive Data Systems experts will come to your location to help make system installation, set-up, and configuration worry-free.
EDS employs highly skilled, customer-driven people to assist in the installation and deployment of our solutions.
In addition, you will find that our implementation teams are creative problem solvers and have extensive experience in the deployment of simple configurations to more complex environments.
Our implementation methods ensure rapid roll-out. System configuration is designed to fulfill your unique business practices and ensure a smooth transition for your personnel. No matter how simple or complex your needs may be, EDS is here to make certain you get a rapid return on your investment.
Our Express Implementation Training Service ensures that you'll enjoy all the benefits the Software has to offer—sooner rather than later. Contact us to schedule your Express Implementation.
Get the full benefits of the Time and Labor Management Software with minimal startup costs and rapid implementation. A hosted solution allows your to outsource your Timekeeping Software avoiding the problems and expense of maintaining the network infrastructure and required IT support. Our SaaS systems reside on secure and redundant off site servers which are available 24 hours a day 7 days a week. Your software is constantly updated, backed up and Premium Support is included for one low monthly fee.
Our Saas program is a pay as you go which gives you unlimited access to your Time and Labor Management System. Access is by setting up specific secure user passwords with state of the art encryption and firewall protection.
Low monthly fee (pay as you go).
Employees can view and approve their own timecard.
Clock extended Service coverage is required on all SaaS programs. Per month cost depends on the model and number of clocks.


180 records – page 1 of 18.
[50-year nightmare. Interview by Lars Peter Bergqvist].
Account of the Russian discoveries between Asia and America. To which are added, the conquest of Siberia, and the history of the transactions and commerce between Russia and China.
3d ed., revised and corrected. T. Cadell, London. 454 pp.
From: Fortuine, Robert et al. 1993. The Health of the Inuit of North America: A Bibliography from the Earliest Times through 1990. University of Alaska Anchorage. Citation number 593.
Across arctic America; narrative of the Fifth Thule Expedition.
G.P. Putnam's sons, New York. 388 pp.
Alaska Medical Library - From: Fortuine, Robert et al. 1993. The Health of the Inuit of North America: A Bibliography from the Earliest Times through 1990. University of Alaska Anchorage. Citation number 377.
UAF - Rasmuson Library G670 1921.R35 ALASKA, G700 1921.R3813 1999 ALASKA [1999 edition].
Alaskan voyage, 1881-1883: an expedition to the northwest coast of America. Translated by E. Gunther from the German text of A. Woldt.
University of Chicago Press, Chicago. 266 pp.
Alaska Medical Library - From: Fortuine, Robert et al. 1993. The Health of the Inuit of North America: A Bibliography from the Earliest Times through 1990. University of Alaska Anchorage. Citation number 345.
Ameliorative value of carbohydrate and electrolytes in arctic survival.
An Eskimo village in the modern world.
Cornell University Press, Ithaca, NY. 419 pp.
From: Fortuine, Robert et al. 1993. The Health of the Inuit of North America: A Bibliography from the Earliest Times through 1990. University of Alaska Anchorage. Citation number 63. UAA/APU Consortium, Alaskana Collection E99.E7 H95 1962. UAF - Rasmuson Library E99.E7 H95 ALASKA.
Apaurak in Alaska: social pioneering among the Eskimos. Translated and compiled by W. Johnshoy.
Dorrance & Co., Philadelphia, PA. 325 pp.
Alaska Medical Library - From: Fortuine, Robert et al. 1993. The Health of the Inuit of North America: A Bibliography from the Earliest Times through 1990. University of Alaska Anchorage. Citation number 307.


text:
On Mar 24, 2019 6,704
Joe Budden Net Worth 2019 – Joseph Anthony Budden II is an American broadcaster, former rapper, and songwriter. Budden's eponymous debut studio album was released in 2003 and debuted at number 8 on the Billboard 200, selling 95,000 copies within its first week.
According To Forbes, Joe Budden Net Worth 2019 is $6 Million. He entered a drug rehabilitation program at age seventeen. He began a relationship with Cyn Santana in 2016; they announced they were expecting a child together in September 2017. He was previously romantically linked to model Esther Baxter . He has a son named Trey.
Joe Budden Net Worth 2019 is $6 Million
Middle Name: Anthony
Last Name: Budden
Full Name: Joseph Anthony Budden II
Birthday: 31st August, 1980
Birthplace: Spanish Harlem, NY, USA
Hair C: Bald
Zodiac Sign: Virgo
Religion: Baptist
Ethnicity: Multiracial
High School: (dropped out, GED)
Profession: Rapper, Songwriter
Claim to Fame: New Jersey rapper/mixer
Year(s) Active: 2002 – present, 2003-present, 2003–present
Record Label: Mood Muzik Entertainment, E1 (present), Roc-a-fella records, Desert Storm, Def Jam (former), Mood Muzik, eOne (solo; present), Shady, Interscope (Slaughterhouse; present), Desert Storm, Def Jam (solo; former), Mood Muzik, Amalgam Digital, eOne (solo; present)
Associated Acts: Slaughterhouse, Slv, Emanny, Fabolous, Slv
Talent Agency: ICM Partners (LA)
Websites: http://www.joebuddentv.com/, instagram.com/joebudden/?hl=en, twitter.com/joebudden
Associated People: Christina Milian
American rapper with the group Slaughterhouse who is best known for his solo single "Pump It Up." He is known to television audience for co-starring on the VH1 reality show Love & Hip Hop: New York .
He was featured on Marques Houston 's 2003 single, "Clubbin." He released the number-one rap album Welcome to: Our House with Slaughterhouse in 2012.

redpajama_set_name: RedPajamaCommonCrawl


While our podcast is heart of HOTDROP, the soul is our Discord: Our thriving community of gamers from all over the world and across all platforms.
The HOTDROP Discord is a free chat program for desktop and mobile where you can stay up to date on the latest news, make new friends, and find others to play with!
Share pictures of your pets, food and drink, or your battlestation; submit clips to the Top 10 or Challenge of the Week, get gameplay tips and advice, or give us feedback!


text:
Home / Tennis News / "Queens Tennis" Is Now "The Fever-Tree Championships" • Kyle Edmund To Play • Feliciano Lopez To Return To Scene Of His Greatest Triumph • Buy Tickets!
"Queens Tennis" Is Now "The Fever-Tree Championships" • Kyle Edmund To Play • Feliciano Lopez To Return To Scene Of His Greatest Triumph • Buy Tickets!
Fever-Tree Championships
The Queen's Club
18-24 June, 2018
Editors Note: One of The Worlds best tennis events (My Favorite) just brought a GREAT new sponsor to tennis. We love Fever Tree. As they say on their bottle if 3/4 of you drink is mix why not have the best ? We love the Ginger ale. We love the tonic water.
• All gin companies welcome to join the party.
Pimms with Fever-Tree… (Makes yummy yummier)… ginger ale? NoGinger beer? Fuzzy (bubbly) something.
We love the flavors but best of all… natural ingredients. All natural. No sweeteners no preservatives. No flavourings.
We are guessing new background color for the queens club will be Fever -Tree trademark gold..?.. Yellow… Please bring me a pitcher of Pimms…. (LJ)
Fever-Tree Championships – Edmund To Play In Britain As Nation's No.1 Ranked Man For First Time; Lopez To Return To Scene Of Greatest Triumph
British No.1 Kyle Edmund and defending champion Feliciano Lopez have added their names to a star-studded list of players intending to play in the newly-named Fever-Tree Championships at The Queen's Club, 18-24 June.
Edmund and Lopez will join 3 of the world's current Top 4 ranked players – Rafael Nadal (2), Marin Cilic (3), Grigor Dimitrov (4) – and 5-time champion Andy Murray in entering the tournament which yesterday announced Fever-Tree, the premium brand mixer-drinks company, as its title-sponsor.
Edmund became the British No.1 after a stunning run to the semifinals of the Australian Open in January, replacing Murray who has endured an extended absence from the game because of injury. Edmund's appearance at the Fever-Tree Championships will be his first in Britain since becoming his nation's No.1 ranked male player. Murray held the British No.1 position for nearly 12 years.
"I am very much looking forward to playing the Fever-Tree Championships in June," said Edmund, who beat Dimitrov to reach the semifinals in Melbourne before going down to Cilic in the final four.
"Competing in front of British tennis fans at home is always a thrill, and I would love to do well at The Queen's Club. The tournament is one of the best of the year with so much history. With Wimbledon just around the corner I really want to see what I can do on the grass. The transition to grass is always a challenge, but I think I'm getting better at it. I've got another year of experience on the tour and this is an opportunity for me to put that on the court.
"It'll be a really good feeling to go to the Fever-Tree Championships at Queen's as British No.1. It's a combination of me doing well and Andy dropping down the rankings because of injury, but I'm happy to be there. I'm not going to just stop working hard because I'm there. The expectations will be high, that's normal. I've just got do my best."
Lopez won the title at his 12th attempt, defeating Cilic in one of the best finals in the event's history.
"Winning the trophy at Queen's meant everything to me," said Lopez. "Outside the Slams I think it is one of the biggest tournaments in the world to win because of the history, the club, the trophy. It is unique. After trying for more than 10 years and losing against Grigor (Dimitrov) after having match point in the 2014 final, it was so, so special to finally do it – one of the best moments of my whole career. I will be so proud to come back to the Fever Tree Championships to try to defend my title."
Stephen Farrow, Tournament Director, said: "We are delighted to add Kyle and Feliciano's names to the Fever-Tree Championships line-up just a day after our new title-sponsor came on board. Kyle has played well at The Queen's Club before, reaching the quarterfinals two years ago, but over the past few months he has reached another level. It will be a special moment to see him make his first appearance in Britain as the nation's No.1 male player, on our centre court.
"Feliciano winning this title a year ago touched everyone, and it was just an amazing final. He is one of the most popular players every year, both on court with the crowd and off it behind the scenes with all the staff at the tournament. We can't wait to see Kyle and Feliciano in June."
Tickets for the Fever-Tree Championships went on sale recently amidst record demand. The tournament's Centre Court capacity increased by more than 30% last year. The event will be covered throughout by BBC television, radio and online, by Amazon Prime Video for the first time and around the world in more than 40 countries.
Tickets and hospitality packages are available here – https://www.lta.org.uk/major-events/fever-tree-championships/tickets/
The Fever-Tree Championships
ABOUT FEVER-TREE
Fever-Tree is the world's leading supplier of premium carbonated mixers for alcoholic spirits by retail sales value, with distribution to over 60 countries worldwide. Based in the UK, the brand was launched in 2005 to provide high quality mixers which could cater to the growing demand for premium spirits, in particular gin, but also increasingly for vodka, rum and whisky. The Company now sells a range of carbonated mixers to hotels, restaurants, bars and cafes ("On Trade") as well as selected retail outlets ("Off Trade"). www.fever-tree.com
ABOUT THE LTA:
The Lawn Tennis Association (LTA) is the National Governing Body for tennis in Great Britain, responsible for developing and promoting the sport, with a mission to get more people playing tennis more often. It does this under the consumer brand of British Tennis, by working with a broad range of partners and over 25,000 volunteers, to grow the game in communities, clubs and schools. The LTA represents the interests of over 590,000 British Tennis Members, men and women, girls and boys across the country, playing on more than 23,000 courts. The LTA runs and supports a network of 11,500 approved tournaments for players of all ages, the corner-stones of which are the premier grass court events leading up to Wimbledon, held in Nottingham, Birmingham, Queen's Club-London and Eastbourne. The LTA works with many delivery partners to grow the sport across the country. One of these is its charitable entity, the Tennis Foundation, to provide a tennis provision for more than 20,000 schools, disadvantaged youth as well as promoting tennis as an inclusive sport for anyone with a disability. For further information about the LTA and British Tennis, and to review the British Tennis strategy for 2015 – 2019 visit www.lta.org.uk or follow us on Twitter @BritishTennis.
10sballsAndy MurrayAtpFeliciano LopezFever-TreeFever-Tree ChampionshipsGRIGOR DIMITROVKyle EdmundLondonLtaMen's tennisQueen's ClubRafael Nadaltennistennis news
← Previous Story WTA Ladies Tennis Update From Charleston Via Cignarelli's Volvo Car Vantage Point
Next Story → Tennis 10sBalls Talks Tennis • Save Davis Cup by BNP Paribas


text:
RHS Announces PTA Reflections Winners
Submitted by the Rutherford School District
The Rutherford High School English and music departments are thrilled to announce the winners in this year's PTA Reflections contest. Each year, students in Pre-K through Grade 12 are invited to create and submit original works of art in the areas of Dance Choreography, Film Production, Literature, Music Composition, Photography, and Visual Arts.
This year, Rutherford High School had four state-level winners and one national winner!
On the state level, we are proud to announce that:
Katie Whaley won the Award of Excellence in Literature for her piece called, "Living in Me."
Julia Lorenz won the Award of Merit in Literature for her piece called, "Isolation."
Katie Corcoran won the Outstanding Interpretation Award in Music Composition for her piece called, "Mindfulness."
Sarah Dzurillay won the Award of Excellence in Music Composition for her piece called, "Look Within."
Daniel Gregory won the Honorable Mention in Music Composition for his piece called, "Invasion."
All of these winning pieces advanced to the national competition and RHS is excited to announce that Katie Corcoran won an Award of Merit in the nationwide contest. Her work will now be showcased in January 2021 at the U.S. Department of Education in Washington, DC, and June 2021 at National PTA's Convention & Expo in Grapevine, TX.
Congratulations to all!


This is a great event for family participation. It is part of our mercy/compassion ministries. We meet at the church to prepare a simple meal and then go downtown as a group to distribute the food. Contact the church office (brvineyard@brvineyard.org or 225.751.0936) with any questions.


Particle Presets Kit is a powerful After Effects template that allows you to create thousands of different variations of particles effects. This template contains 20 basic presets with 14 control options including; size, color, bokeh, glow, 3d spheres and so many more. You can use different combinations to make cool looking effects like fireflies, magical spheres and sparkling particle trails. Trapcode's Particular Required.


Joe Biden recently visited Kopps Custard in Greenfield, Wisconsin and got custard on his face! He asked the manager how much he owed him, and the manager replied "lower our taxes"; see that on the attached video, and note that Biden later called him a "smartass" (link).
This is all great fun and quite entertaining, but considering the massive problems the U.S. is having none of it is helping. In case anyone would like to do things that are effective - things that would hold politicians accountable and that would undercut the mainstream media - help promote the question authority plan.
You can rant at a politician all day, and they'll just keep on doing what they've been doing. Rants and having "fun" aren't effective. The way to change politicians' behavior is to ask them tough questions designed to show the flaws in their plans, what they aren't mentioning, and so on.
The media refuses to ask politicians tough questions, and citizens who get the chance - at custard shops or at townhalls - aren't filling the gap.
Asking tough questions would help hold politicians accountable and at the same time it would show up the mainstream media.
If you want to hold politicians accountable and show up the mainstream media, help promote the question authority plan.
UPDATE: This was in Wisconsin, not Michigan as initially stated.
Custard shop mgr to Joe Biden: "Lower our taxes"


Gynecomastia is a condition where men develop female-like breasts. Physiological gynecomastia occurs from a temporary hormonal imbalance during puberty. If this does not resolve by early adulthood, then it is amenable to surgical correction. Other causes of gynecomastia are obesity, excessive alcohol intake, marijuana use, and anabolic steroid use.
Gynecomastia is managed surgically by excision of prominent breast tissue and/or liposuction.


text:
Q: Using Delimiter in MYSQL Must I use delimiter in Mysql to create a procedure?

A: Yes you must - unless your procedure is made of a single statement. This is well explained in the documentation:

Each stored program contains a body that consists of an SQL statement. This statement may be a compound statement made up of several statements separated by semicolon (;) characters.
[...]
If you use the mysql client program to define a stored program containing semicolon characters, a problem arises. By default, mysql itself recognizes the semicolon as a statement delimiter, so you must redefine the delimiter temporarily to cause mysql to pass the entire stored program definition to the server.
To redefine the mysql delimiter, use the delimiter command. [...] This enables the ; delimiter used in the procedure body to be passed through to the server rather than being interpreted by mysql itself.

A: Yes in a Query tab or in the mysqlclient you need them as described here
The problem is a semicolon is the end of a command, but in a stored procedure all semicolons a prt of the stored procedure.
Mysql has to now when he must interpret, the semicolons as part of the procedure by having the DELIMITER changed

redpajama_set_name: RedPajamaStackExchange


text:
Breaking: Argentinian football legend, Maradona passes away aged 60
Diego Maradona has died of a heart attack just two weeks after being released from hospital after treatment for a bleed on his brain
The football legend had a heart attack at his home just two weeks after leaving hospital where he underwent surgery on a blot clot in his brain.
Maradona, regarded as one of the greatest footballers of all time, helped Argentina win the World Cup in 1986, the pinnacle of an illustrious career.
He played club football for Boca Juniors, Napoli and Barcelona among others and was adored by millions all over the world for his brilliant skills.
Maradona was responsible for the infamous 'Hand of God' that eliminated England from the 1986 tournament.
His career was also tinged with controversy because of drug and alcohol addiction.
Election 2020: Don't allow politicians to use you-Peace Council advises the youth
Peace Council Chair shares the two principles that this current generation needs to learn


Communication Theory and Practice Communication in human life has become so important and promising, however, how to effectively communicate either by oral or writing is not an inherent talent, which believably can be trained step by step. People even think that an attractive communication just kind of art. It can't be copied or formulated because man is always changeable. In this course, instructor will follow the textbook as well as give practical case study by two-way interesting method. How to let the students open their minds with happiness and feel humorous in the class is primary task for a qualified teacher. Besides, students will fully use this skill learnt from class into his future work.


Then came the fists, and the boots, as a group of self-proclaimed skinheads attacked Paul Morris in the Jackman Inn in Avalon.
But that wasn't how the Avalon Police Department initially saw the July 7 assault. The first responding officer, Craig Cannella, said everyone—including Morris, who is African American—would receive citations for disorderly conduct. In fact, other than speaking briefly to the bartender and chef—whom Morris had gone there to thank for catering a party, and who tried to break up the assault—no witness interviews were conducted until reports of the assault hit local papers and television news nine days later.
Only then did the department start the process in filing assault charges against six members of the Keystone State Skinheads who attacked Morris: Natasha Dawn Bowers, 33, of Roaring Spring; Terrence Raymon Stockey, 40, of Beaver; Jeremy L. Ingram, 35, of Hollidaysburg; Travis Lee Cornell, 43, of Marianna; Crystal Lynn Shields, 23, of Tarentum; and James Edward Kryl, 45, of the North Side.
Avalon Police Chief Thomas Kokoski did not return calls to the Courier for comment.
Jackie Scanlon, the general manager at the Jackman Inn, said even though several of them were apprehended at the scene, all were let go.
Morris said he decided to go to attorney Fred Rabner, who also represented Leon Ford, after the police did nothing.
Morris actually did try to leave but couldn't—the skinheads blocked his way, according to Morris. Morris had come to the bar to drop off a thank-you card for his friend, head chef Javon Jenkins, for cooking the food for a graduation party for Morris' son. He and Jenkins were on the bar's back deck smoking when a group of men and women confronted them, calling them n____rs.
Morris told the Courier he is pleased charges were eventually filed, but said he feels the Avalon police dropped the ball with this incident. Still, he wants to put the incident behind him, as much as possible.


text:
OHCHR > English > News and Events > DisplayNews
Press briefing notes on Turkey, Israel and Bahrain
(1) Turkey
In a press release issued this morning, High Commissioner Zeid called on Turkish authorities to respond to the attempted coup by reinforcing the protection of human rights and by strengthening democratic institutions and checks and balances.
"I deplore the loss of so many lives in Turkey over the weekend, and offer my sincere condolences to the families of those who were killed," he said. "The Turkish people bravely took to the streets to defend their country against those who sought to undermine its democracy. I urge the Government of Turkey to respond by upholding the rule of law, by strengthening the protection of human rights and by reinforcing democratic institutions. Those responsible for the violence must be brought to justice with full respect for fair trial standards."
"In the aftermath of such a traumatic experience, it is particularly crucial to ensure that human rights are not squandered in the name of security and in the rush to punish those perceived to be responsible," he added.
The full statement is available here: http://www.ohchr.org/EN/NewsEvents/Pages/DisplayNews.aspx?NewsID=20282&LangID=E
(2) Israel
We are concerned at the passing on 11 July of the so-called NGO Transparency law by the Israeli Parliament, which could have a detrimental effect on human rights and the democratic space in the country.
While this new law has been described as an effort to increase transparency in the NGO sector, it will disproportionately affect NGOs working on human rights, as confirmed by recent research undertaken by the Israeli Ministry of Justice itself.
The law imposes new requirements on NGOs that receive more than half of their funding from "foreign political entities", namely foreign governments or intergovernmental organizations, obliging them to specify this information in their publications and their communications with civil servants or elected officials. The same is not required of NGOs that are funded by other foreign sources that are not classified as political entities or by private donors.
We fear that this law, which adds to already onerous transparency obligations on NGOs receiving funding from foreign political entities, will contribute to the de-legitimization of human rights NGOs in Israel, notably by branding them as "foreign agents".
Given the recent attacks against civil society organizations in Israel by public officials and some specific groups, we fear that this law will have a chilling effect on human rights defenders and their legitimate and extremely valuable contribution to the human rights debate in Israel, including those challenging the Israeli Government's policy on the occupied Palestinian territory.
We note that many NGOs in Israel, including ones not themselves affected by the law, have strongly criticized it, as have the Secretary-General, the European Union and individual donor governments. We urge the Government to listen to these extremely valid concerns and take them into consideration.
(3) Bahrain
We deeply regret the decision by a Bahraini court on Sunday to dissolve Al Wefaq, the country's largest opposition group, following its initial closure on 14 June. In spite of strong calls from the international community for Bahrain to seek to de-escalate the worrying tensions in the country, we regret the decision to press ahead with the ban. Reports suggest that the court hearing on the ban was carried out without due regard for the principles of fair trial.
The ban on Al Wefaq is the latest in a series of measures over the last few months that appear to be designed to quash dissent. We urge the authorities, and the national human rights institutions in place in Bahrain, to take immediate confidence-building measures to ensure the rights to freedom of peaceful expression, assembly and association are respected. We urge them to review the decision to ban Al Wefaq and other organisations that have been suspended for peaceful exercise of their rights.
For more information and media requests, please contact please contact Rupert Colville (+41 22 917 9767 / rcolville@ohchr.org) or Ravina Shamdasani (+41 22 917 9169 / rshamdasani@ohchr.org ) or Cécile Pouilly (+41 22 917 9310 / cpouilly@ohchr.org)
For your news websites and social media: Multimedia content & key messages relating to our news releases are available on UN Human Rights social media channels, listed below. Please tag us using the proper handles:
Twitter: @UNHumanRights
Facebook: unitednationshumanrights
Instagram: unitednationshumanrights
Google+: unitednationshumanrights
Youtube: unohchr


IIllustrator Kari Modén is based in Stockholm, Sweden. After one year of preliminary education of art Kari moved on to study graphic design and illustration at RMI Berghs School 1983-85. She started off as an Art Directors assistant and whilst studying typography for the renowned Swedish typographer Carl-Fredric Hultenheim.
Having a great sense of using colour Kari uses her bold and expressive style to mix simple shapes with type.
Inspired by pop-art, South American poster design, fashion and magazines Kari contributed many illustration/design books which are sold in museum and book shops all over the world.
Her unique and distinctive style has been appreciated by various clients within Scandinavia and worldwide. With her strong integrity and personal style and touch Kari's been commissioned for advertising and editorial work, packaging, patterns, t-shirt prints, wall paintings and websites. One of Sweden's biggest ecological brand Saltå have commissioned Karis illustrations for a range of their products which has been awarded for their designs.
H&M/Sweden, J&B whisky/NL, Lascivious/UK, Sokos stores/Finland.


text:
Role of iodine, selenium and other micronutrients in thyroid function and disorders.
Micronutrients, mostly iodine and selenium, are required for thyroid hormone synthesis and function. Iodine is an essential component of thyroid hormones and its deficiency is considered as the most common cause of preventable brain damage in the world. Nowadays about 800 million people are affected by iodine deficiency disorders that include goiter, hypothyroidism, mental retardation, and a wide spectrum of other growth and developmental abnormalities. Iodine supplementation, under form of iodized salt and iodized vegetable oil, produced dramatic improvements in many areas, even though iodine deficiency is still a problem not only for developing countries. In fact, certain subpopulations like vegetarians may not reach an adequate iodine intake even in countries considered iodine-sufficient. A reduction in dietary iodine content could also be related to increased adherence to dietary recommendations to reduce salt intake for preventing hypertension. Furthermore, iodine intakes are declining in many countries where, after endemic goiter eradication, the lack of monitoring of iodine nutrition can lead to a reappearance of goiter and other iodine deficiency disorders. Three different selenium-dependent iodothyronine deiodinases (types I, II, and III) can both activate and inactivate thyroid hormones, making selenium an essential micronutrient for normal development, growth, and metabolism. Furthermore, selenium is found as selenocysteine in the catalytic center of enzymes protecting the thyroid from free radicals damage. In this way, selenium deficiency can exacerbate the effects of iodine deficiency and the same is true for vitamin A or iron deficiency. Substances introduced with food, such as thiocyanate and isoflavones or certain herbal preparations, can interfere with micronutrients and influence thyroid function. Aim of this paper is to review the role of micronutrients in thyroid function and diseases.
Endocr Metab Immune Disord Drug Targets.


text:
Posts from the 'FDA' category
Tocilizumab approved for systemic juvenile rheumatoid arthritis in children
By Pieter Droppert on April 18, 2011
Juvenile rheumatoid arthritis (JRA) is a disease that results in chronic joint inflammation, and is the most common rheumatology disease in children.
The American College of Rheumatology classifies juvenile RA into 3 subtypes, one of which is systemic JRA. The news that the FDA just approved tocilizumab (Actemra®) from Roche for pediatric systemic JRA (SJRA) is therefore good news for several reasons:
1. Very few drug companies obtain pediatric indications for their drug since registration trials are more routinely undertaken with adult patients.
2. In several adult phase III clinical trials, tocilizumab was also shown to delay joint damage as measured by ACR20, ACR50 and ACR70 responses. An ACR 20 response requires a patient to have a 20% reduction in the number of swollen and tender joints.
If you look at the adult phase III clinical data that has been published for the AMBITION, LITHE, OPTION, TOWARD, RADIATE studies, what is noticeable to me is the high percentage of patients across the studies who had an ACR20 response within 24 weeks (70%, 56%, 59%, 61%, 50%); in all cases a significant improvement over placebo plus methatraxate or other disease modifying anti-arthritic drug (DMARD).
Source: Roche data on adult phase III trial results
However, it's clear from the above data that fewer patients had deep responses e.g. ACR50, ACR70. Tocilizumab is a treatment option for those who have failed previous RA therapies, and while not a cure, can provide symptom relief and improve joint function in those suffering from moderate to severe RA.
According to the Roche press release, data from the pediatric study known as TENDER, showed that 64/75 children (85%) of children with SJRA experienced an ACR30 improvement. Given the fact the drug is already approved for adult use, and has extensive phase III trial data, a small pediatric sample size is not unexpected.
A pediatric approval is good news, as all too often pharma and biotech companies neglect this market. I plan to write more in future posts about RA drugs in development as I think this is a market that may continue to evolve new treatment options over the next few years.
Update from AACR on new prostate cancer drugs to watch
The 102nd Annual meeting of the American Association for Cancer Research (AACR) ended yesterday in Orlando, and it was only the diehards who kept going till the last session of the last day for an update on "Novel Androgen Receptor Antagonists."
As I mentioned in an earlier post, there is a lot of excitement in the prostate cancer field at the moment with three new therapies approved last year (cabazitaxel, sipuleucel-T, denosumab), and more expected over the next two years (abiraterone acetate, MDV3100, cabozantinib/XL-184).
What I took from the AACR session I attended, is that there are also other products in the pipeline that are worth watching. Below is a list of some of the products that were mentioned. It's not intended to be a comprehensive review of the prostate cancer landscape, only my notes and thoughts on some of the new products that the speakers touched upon.
Abiraterone Acetate: The postive phase III trial results were reported last year at ESMO and ASCO GU, and the approval of this drug is currently being considered by the FDA. Approval is expected shortly, and possibly in time for launch at the forthcoming annual meeting of the American Urological Association (AUA) meeting in Washington, DC.
Abiraterone (brand name Zytiga) inhibits the enzymes (17-alpha hydroxylase and C17, 20 lyase) responsible for adrenal androgen formation.
The phase III results were impressive in very sick patients who were close to the end of their lives in very advanced disease. Overall survival increased from 10.9 to 14.8 months in the second line chemotherapy setting post docetaxel. It's expected that the results will be more dramatic pre-chemotherapy.
Once the FDA approval is obtained, it's hard to see how oncologists will not consider abiraterone instead of cabazitaxel in the second-line chemotherapy setting. An easily taken pill with fewer less side effects may be a more convenient option for elderly or frail men with prostate cancer. Abiraterone's approval will not be good news for sanofi-aventis.
I also expect we will see significantly off-label usage of abiraterone pre-chemotherapy by urologists as they seek to maintain hormone-sensitivity in their patients after several lines of anti-hormonal therapies. There is a phase III trial ongoing in this setting that is expected to show promising data by the end of the year.
However, it's a good strategy to come market as soon as possible to provide wider access to patients in need, and the post-docetaxel second line setting allowed the overall survival benefit to be shown before the pre-chemo data would be available.
However, what I learned at the meeting is that abiraterone acetate may not be the best product in the long term. Currently it requires the corticosteroid, prednisone, to be given at the same time to attenuate the mineralocorticoid effects. Questions that were raised in the AACR session about long-term treatment with abiraterone included, "Must a corticosteroid be given concurrently?" and "What about hypertension?"
Other questions remain, such as possible development of resistance to abiraterone. Often the first drug to market is not the best, and it's possible that second generation new products in the pipeline may be better than abiraterone and delay the time to resistance further.
However, what abiraterone does have is first mover advantage and depending on the pricing strategy adopted by Johnson & Johnson, the ability to capture market share earlier. It will be interesting to see what happens with this drug, but it's certainly an exciting time for patients with prostate cancer.
TAK-700: This drug from Takeda/Millennium is a more potent inhibitor of C17α-hydroxylase than abiraterone. One of the panelists at AACR believed that TAK-700 "may in the long run surplant abiraterone acetate due to less need for mineralocorticoids." TAK 700 entered phase III clinical trials late last year.
MDV3100: This drug is being developed by Medivation/Astellas and is also in phase III trials, with data expected by the end of this year or early 2012. It has a high affinity for the androgen receptor. However, what came across in the AACR presentation by Howard Scher, was his view that the second compound developed by Charles Sawyers, ARN-509 may be better than MDV3100.
ARN-509: This drug from Aragon Pharmaceuticals is in phase I/II clinical trials and is definitely one to watch. As Dr Scher pointed out, ARN-509 is more potent than MDV3100 and I expect we will see publication of more data on ARN-509 in the near future.
If you are interested in prostate cancer, AACR are offering webcasts and podcasts of scientific sessions this year. Further information can be found on their website. AACR have also announced a scientific special session on "Advances in Prostate Cancer Research" from February 6-9 2012. It's certainly an interesting and exciting time in this field as new products become available, something that is likely to make a real difference to how this disease is treated.
US Supreme Court decision in Matrixx: adverse events may need to be disclosed to investors
By Pieter Droppert on March 23, 2011
In a unanimous decision, the United States Supreme Court decided yesterday that pharmaceutical and biotechnology companies may have an obligation to disclose adverse events to investors, even if the data is not statistically significant.
I previously discussed the case of Matrixx Initiatives, Inc. v. Siracusano on this blog and correctly predicted that the Supreme Court would uphold the decision of Court of Appeals for the Ninth Circuit. The result is a valid securities class action fraud claim that can now go to trial, or more likely, a financial settlement will be worked out.
You can read more on the background to this case in my previous post, but at issue was whether Matrixx Initiatives, Inc. (Matrixx) mislead investors by not disclosing reports that some consumers had lost their sense of smell (anosmia) after using Zicam Cold Remedy. Despite product liability lawsuits, complaints from consumers and medical scientists drawing the company's attention to previous studies linking zinc sulfate (contained in the Zicam nasal gel) to loss of smell, Matrixx continued to be optimistic to investors about the company's performance and prospects.
In the November 2003 Form 10-Q filed with the Securities and Exchange Commission (SEC), the company made no disclosure that two lawsuits had been filed over alleging use of Zicam had caused a loss of smell.
The decision in Matrixx Initiatives, Inc., v. Siracusano case has major implications for investor relations, public relations and corporate communications departments of publicly traded companies within the biopharmaceutical industry.
Under U.S. Securities and Exchange Commission (SEC) Rule 10b-5 companies have an obligation to disclose material facts related to statements that are made that could impact the purchase or sale of stock i.e. you have to provide all the information necessary to avoid a statement being misleading. This does not mean that companies have to share all material information about their products, they control what they say, but what they say has to contain all the material facts necessary for it to be truthful and accurate.
Say a major pharma company issues positive press releases at a major medical congress announcing great clinical trial results, while at the same time the Data Monitoring Committee (DMC) is meeting to terminate the study because the drug has too many adverse events. My reading of the Matrixx decision is that the company cannot make the positive statements without including the information about their concerns about adverse events. In those circumstances they might be better off not making the positive press releases, rather than potential misleading investors into buying stock on the back of this data, when the drug may end up being terminated shortly afterwards.
As Justice Sotomayor states in her opinion, "the materiality of adverse event reports cannot be reduced to a bright-line rule." Matrixx Initiatives, Inc. v. Siracusano, 563 U.S. ___ (2011) (slip op., at 1-2).
The presence or absence of statistical significance is not the key factor as to whether an adverse event is material or not.
"A lack of statistically significant data does not mean that medical experts have no reliable basis for inferring a causal link between a drug and adverse events."
(slip op., at 12). As Justice Kagan noted in her questioning at oral argument and Justice Sotomayor picked up in her opinion, "[t]he FDA similarly does not limit the evidence it considers for purposes of assessing causation and taking regulatory action to statistically significant data." (slip op at 13).
Justice Sotomayor goes on to conclude that reasonable investors may also base their decision on non-statistically significant data. The challenge that the industry now faces is determining what information is "material" and needs to be disclosed. A bright-line rule of statistical significance would have made this easy.
Companies, their investor relations and public relations agencies are now faced with the question of what is "material", and what is not. The guidance the court offers is that:
"assessing the materiality of adverse event reports is a "fact-specific" inquiry that requires consideration of the source, content, and context of the reports."
(slip op., at 15, citations omitted). The Court notes this does not mean that "pharmaceutical manufacturers must disclose all reports of adverse events" only those for which "a reasonable investor would have viewed the nondisclosed information as having significantly altered the total mix of information made available" (slip op., at 15, citations and quotation marks omitted).
So should all adverse events be reported? That's one possible way to avoid deciding what's material, but Justice Sotomayor, clearly states that this is not the standard to be applied. She states,
"mere existence of reports of adverse events which says nothing in and of itself about whether the drug is causing the events – will not satisfy the standard."
(slip op., at 16). What is needed is some link between the adverse event and the drug that suggests possible causality, what Justice Sotomayor describes as a "contextual inquiry." She goes on to say that it is this contextual inquiry that can come from other sources or reports. In the Matrixx case this would have come from the filing of lawsuits, the concerns of academics about causal links, consumer complaints, the presentation of a scientific poster etc.
"This contextual inquiry may reveal in some cases that reasonable investors would have viewed reports of adverse events as material even though the reports did not provide statistically significant evidence of a causal link."
(slip op., at 16). The conclusion from the Matrixx case is that publicly listed companies should be very careful of the information that they tell the market. As Justice Sotomayor notes:
"Even with respect to information that a reasonable investor might consider material, companies can control what they have to disclose under these provisions by controlling what they say to the market."
(slip op., at 16). Whatever information is given to the market e.g. investor presentations at conferences, press releases, press briefings or SEC reports, the information should not be misleading through the omission of material facts.
What the Matrixx decision does is include adverse events as possible material facts, even those adverse events that have not been proved to be causal, or have reached statistical significance. The conclusion being that disclosure of adverse event data may need to be included, if the omission of this information could impact the decision making of a reasonable investor.
In practice, clinical departments and medical affairs will need to be more closely involved with investor relations, and judgments will have to be made as to what information is disclosed. Any time a judgment is required, there are likely to be differences in opinion as to what is "material" or not. Prudent companies should consider sharing more information rather than less, but how to do this in a way that does not overburden investors will be the challenge.
NYC Medical Technology Life Sciences Networking Event
By Pieter Droppert on February 10, 2011
After I wrote my previous blog post about the emerging biotechnology region around Austin, TX, one of the comments I received was about the importance of networking opportunities within a cluster or region.
So I am pleased to have been invited to a medical technology-life science networking event in New York City (NYC) organized six times a year by Ted King of Saddlerock Advisors, Wendy Brown of Merrill Lynch and John Lieberman of Perelson Weiner.
The event, later today, has a format of a featured speaker and presentations by three emerging companies that provides them with the opportunity to network and showcase their technology, new drugs or medical devices to investors, industry partners, academics and researchers.
This evening there is a presentation on the proposed changes to the FDA's 510(k) clearance process for medical device approval. This is the route by which the majority of medical devices come to market by showing they are comparable to an existing approved or marketed product.
The three featured companies include BioView (an Israeli technology company involved in cell imaging and automation of genetic testing), Cel-Sci (a Virginia based biotech company that has as immunotherapy product in development about to enter a global phase III clinical trial in head and neck cancer) and PatienTech (a company that develops elastic-sheet, pressure sensing systems that can be used with medical devices).
It will be interesting to see who attends, and whether the presentations by the companies are what I consider to be the typical investor "puff and fluff" presentations, or whether there is any meaningful discussion of science, marketing strategy and new product development.
MIM Software receives FDA approval for iPhone and iPad Imaging App
By Pieter Droppert on February 7, 2011
Following on from my blog post last week that discussed the use of iPads and other tablet computers in clinical trials, MIM Software have just received FDA 510(k) clearance to market their iPhone and iPad medical imaging app in the United States. This is the first such approval by the FDA, and the app will be sold in Apple's itunes store.
This new mobile radiology application will allow physicians to review medical images on their iPhone and iPad. The FDA in their press release indicate that it is not intended to replace full work stations, but to provide the ability to view images and make diagnoses when a workstation is not readily available.
The FDA reviewed luminance, image resolution quality, and results from demonstration studies with radiologists that showed that images could be safely interpreted for diagnostic purposes under appropriate lighting conditions.
What is more, using software from MIM, the images can be further analyzed and distance measurements made.
The ability to have wireless access to medical images will be particularly useful to physicians working remotely, in emergency situations and in clinical trial networks where the central imaging review facility may not be local.
As the screen resolution of iPad's and other tablet computers increases, perhaps we will see advanced visualization software available on the iPad? It is certainly an area where innovation is taking place, and one that I think will impact clinical research in the biotechnology industry before too long.
U.S. Supreme Court to decide if only statistically significant adverse events need to be disclosed to investors
In a case that is set to have major impact on the biotechnology industry, the United States Supreme Court heard oral argument yesterday in the case of Matrixx Initiatives Inc. v. Siracusano. The question presented to the court is:
"Whether a plaintiff can state a claim under § 10(b) of the Securities Exchange Act and SEC Rule 10b-5 based on a pharmaceutical company's nondisclosure of "adverse event" reports even though the reports are not alleged to be statistically significant."
You can find all the briefs and documents related to the case on the excellent Scotusblog. website. A transcript of yesterday's oral argument has been published on the U.S. Supreme Court website.
At issue is whether knowledge of possible adverse events is material information that must be disclosed to investors, even if not statistically significant. The biotechnology industry argue that such a requirement would impose an unreasonable burden upon them and could lead to drugs not being developed.
Matrixx Initiatives is a pharmaceutical company that sells OTC cold remedy products including Zicam Cold Remedy Nasal Gel that was recalled in 2009 following an FDA determination that the product was not safe. During the period 2002- 2004 the company became aware of reports that use of its nasal gel was linked to a loss of smell, anosmia. The company did not announce this information to investors until after several law suits were filed and several notifications of a possible link between the smell loss and Zicam nasal gel had been made to it.
Shareholders subsequently brought a class action law suit alleging that the company and its executives violated the Securities Exchange Act of 1934 by failing to disclose material information. The District Court granted Matrixx's motion to dismiss the complaint and action for a failure of the shareholders to make a claim. The U.S. Court of Appeals for the 9th Circuit in a June 2009 opinion reversed this decision, and the U.S. Supreme Court granted a writ of certiorari to hear an appeal.
Rule 10b-5 of the Securities and Exchange Commission (SEC) states that:
"It shall be unlawful for any person directly or indirectly…. to make any untrue statement of a material fact or to omit to state a material fact …in connection with the purchase or sale of any security."
In the Matrixx case, the shareholders claimed that the failure of the company to disclose information regarding the possible link between Zicam and anosmia was the omission of a material fact. In other words had they known that there was a possibility that Zicam could cause a loss of smell, they would not have bought shares in the company at the price they paid for them or would have sold them.
What is the standard for deciding if something is material? It is "…whether there is a substantial likelihood that a reasonable shareholder would consider the fact important" TSC Industries, Inc. v. Northway, Inc., 426 U.S. 438, 449 (1976).
The District Court dismissed the complaint against Matrixx on the basis that the reports of anosmia were not statistically significant, and therefore not material.
The U.S. Court of Appeals for the 9th Circuit reversed the trial court's decision, based on the U.S. Supreme Court decision in Basic Inc. v. Levison, 485 U.S. 225, 236 (1988) that held "[t]he determination [of materiality] requires delicate assessments of the inferences a "reasonable shareholder" would draw from a given set of facts and the significance of those inferences to him."
The 9th Circuit rejected the use of a bright line test of statistical significance as the standard to apply in deciding whether data was material or not. Instead, the Court of Appeals engaged in a fact-specific inquiry and concluded that between 2002 and 2004 there was sufficient information to make a plausible claim that should be put to a jury.
In reversing and remanding the district court's dismissal of the shareholders action, the 9th Circuit concluded that "the District Court's reliance on the statistical significance standard to conclude that Appellants failed to establish materiality is inconsistent with the Supreme Court's rejection of bright-line rules and its emphasis on having materiality determined by the trier of fact."
The case is now on appeal to the United States Supreme Court, and several leading biotechnology associations have filed amicus briefs seeking to have this decision over-turned. Bay Bio argue that the non-disclosure of statistically insignificant adverse event reports does not make a company's statements about its products or earnings fraudulent under the securities laws. Bay Bio raises the concern that failure to disclose isolated reports of adverse events, even if not medically or statistically significant, will lead to potential liability. In their amicus brief, Bay Bio argue that:
"If left standing, the Ninth Circuit's rule will require companies to make boilerplate disclosures of adverse event reports virtually every time that they make a statement, along with a disclaimer that the company does not believe that such reports have any bearing on their statements. Such an information dump will add nothing to the mix of information already available to reasonable investors. At the same time, such disclosures will needlessly cause consumers to avoid using safe, beneficial drugs."
I am not sure that I agree with this position. Are adverse events material information – yes? If only statistically significant data mattered, then scientific papers and presentations of clinical trial results would not include non-significant information. In fact, an adverse event may be significant in one trial and not in another, based on the sample size, power of the study, patient selection criteria and clinical trial design.
I am not persuaded that only statistically significant data are material to physicians, investors and patients.
As to the burden on the industry, I am also not sure that I accept the dark picture painted that making adverse event data available will be an unreasonable burden, in light of existing reporting mechanisms. One has to remember that Zicam nasal gel, the product in question in this case, was being sold to consumers – it was not an investigational product. Looking at the totality of the information about a potential serious adverse event such as loss of smell, one has to believe that after several reports and law suits, there was some obligation to let investors and consumers know.
What's the outcome in the U.S. Supreme Court – clearly to grant a writ of certoriari, there are at least four justices who wish to hear this case. Whether they have a pro-business view that requires this case be overturned or a pro-consumer view that favors full disclosure of information to investors, I have no crystal ball as to the outcome.
Justice Kagan in oral argument was razor sharp, noting that:
"the FDA takes action all the time as to drugs, they force the withdrawal of a drug from the market, they force relabeling of a drug on the basis of findings that are not statistically significant. Now, clearly in those cases the market has a right to know the very things that are going to make the FDA take action against a product and that are going to severely affect the product's value to the company. Not statistical significance there."
She pointed out to Jonathan Hacker, Esq. the attorney for Mattrix that he was:
"suggesting a test for what counts as material, which is statistically significant, a test that the FDA itself doesn't use when it thinks about what it should what should regulate."
Justice Kagan clearly was on good form and went on with the following hypothetical, how would you answer it?
"There's a pharmaceutical company and it comes out with its first and only product, it's 100 percent of the sales, and it's a new contact lens solution. And it sells this product to many, many, many hundreds of thousands of people. And most of them use this product with no adverse effect whatsoever, but there are ten cases where somebody uses this product and they go blind. Three of those ten cases, the person had to borrow a contact lens from a friend, only used it in one eye, they go blind only in that one eye. This is not statistically significant. There is no way that anybody would tell that you these ten cases are statistically significant. Would you stop using that product and would a reasonable investor want to know about those ten cases?"
My answer would be "yes" I would want to know and even though not statistically significant, this is material information that I would want to know about before it was talked about on "Good Morning America" and everyone then dumped their stock.
So at the risk of alienating those in the biotechnology industry who think otherwise, my money is that the court will uphold the 9th Circuit opinion and not impose a bright line rule that materiality is governed by statistical significance. We can expect a decision towards the summer on a case that may lead to major changes in how adverse events are reported by pharmaceutical and biotechnology companies.
Amphastar sues FDA
The race to bring a biosimilar version of Sanofi-Aventis' low molecular weight heparin, Lovenox® (enoxaparin sodium), to market had three players, Momenta Pharmaceuticals in partnership with Sandoz, Amphastar Pharmaceuticals and Teva.
The winner was Momenta/Sandoz who (as mentioned in a previous post) recorded $292 million of sales in 69 days post launch. As reported by the Wall Street Journal, Amphastar are now suing the FDA alleging the agency acted arbitrarily in delaying its imports of raw heparin. There certainly seems to be no love lost between Amphastar and the FDA, who earlier this year alleged a conflict of interest between Janet Woodcock, the Director for the Center for Drug Evaluation and Research (CDER) and Momenta as a result of the collaboration that identified the contaminant in chinese heparin that killed patients in 2008. Following an FDA investigation, Woodcook was cleared of any conflict of interest but announced she would not participate in the biosimilar approval decision.
In the run up to the approval, the FDA visited the manufacturing facilities for all three companies. Afterwards the status of the Amphastar application became less certain. Unlike Amphastar, both Teva and Sandoz had prior experience of obtaining FDA approval for biosimilar products.
Given the amount of money at stake, its easy to see why Amphastar are unhappy. However, alleging conflicts of interest and arbitrary practices does not exactly win friends and influence people. I am sure the FDA have a credible factual basis for their decision making, in which case Amphastar is unlikely to get anywhere, other than generate negative publicity for themselves. Others may differ in that opinion, and if you want to read a legal analysis of the Amphastar complaint, the FDA Law Blog's post is worth reading. It also has a link to the actual complaint filed.
The more interesting question is when is the FDA going to approve the Teva biosimilar version of Lovenox®? When this happens, Sandoz's first mover advantage will come to an end and further price erosion is likely. According to Reuters, analysts predict this may happen before the end of 2010.
Update: Amphastar gains FDA approval for generic Lovenox
As reported by Ed Silverman on Pharmalot (September 19, 2011), "Amphastar Pharmaceuticals has finally won approval to sell a generic version of Lovenox"
FDA may seek tighter standards for approval of generics
The news, reported by Bloomberg, last week that generic companies may be subject to stricter FDA standards in order to show therapeutic equivalence is good news for the biotech industry and consumers.
Generic companies have a pretty easy ride in obtaining product approval, and I've long been convinced that the formulation of a brand, and what makes it work can include the so called inactive ingredients and how it is put together. I know of many people who have experienced side effects with generics that they don't have with the branded product.
For this reason, branded generics from the original manufacturer have the ability to retain some market share in the face of generic competition. Sandoz, the generic arm of Novartis uses this strategy to good effect with many mature products. However, if companies instead want to try and maintain a premium priced brand and not adapt to the entry of generics, then they will find their market share erodes extremely fast. Not only is brand market erosion fast with generic drugs, but with biosimilars too.
As reported by Reuters, sales of generic enoxaparin sodium injection, Momenta's copy of Sanofi's anti-thrombotic, low molecular weight, heparin sold as "Lovenox" were $292million in the third quarter of 2010. Sandoz markets enoxaparin on behalf of Momenta. They launched the product on July 23, and achieved $292 million of sales in 69 days. With annual sales forecast to be over $1billion, the biosimilar will be a blockbuster and make a significant dent in the $2.9 billion sales of Lovenox in 2009.
The Boston Business Journal reports that Sandoz/Momenta have captured 60% market share already, which is not good news for Sanofi-Aventis and may explain their desire to make acquisitions such as Genzyme to make up for this loss.
Biosimilars that are fully substitutable for the original product, look likely to erode brands extremely fast. Momenta's success is good for the biotechnology industry and highlights the future market opportunity from development of biosimilars.


text:
Search for cold-stunned sea turtles continues after more than 100 wash ashore on Hatteras
Watch WAVY-TV 10 News at Noon
Bank mistakenly deposits $37M into Texas woman's account
DALLAS, Texas (Associated Press) — A clerical error by her bank made a North Texas woman a millionaire for a day.
KTVT-TV reports when Dallas resident Ruth Balloon checked her bank account earlier this week, it had some extra money in it: $37 million extra to be exact.
Balloon had wanted to believe "someone really gifted us with that $37 million" but she knew it was too good to be true.
Her husband called their bank, LegacyTexas, which informed the couple the extra money wasn't a Christmas miracle but a mistake. The bank apologized and took the money back.
by LISA MASCARO and ZEKE MILLER Associated Press / Jan 22, 2020
NJ is 1st state to mandate severance pay for mass layoffs
TRENTON, N.J. (AP) — New Jersey has become the first state in the nation to guarantee severance pay for mass layoffs, according to the bill's sponsors and the governor's office.
Democratic Gov. Phil Murphy on Tuesday signed legislation that requires companies with 100 or more full-time employees to pay them a week's pay for each year of service during a mass layoff, plant closing or transfer resulting in 50 or more workers losing their jobs. The law also increases the minimum number of days notice from 60 to 90 for such events.
Sailor killed by propeller on USS George H.W. Bush 'lost situational awareness' before accident, report says
by WAVY Web Staff / Jan 21, 2020
(WAVY) -- A report obtained by the Navy Times has found a U.S. Navy sailor killed by a propeller on the flight deck of the USS George H.W. Bush "lost situational awareness" before he was hit.
The report found all rules and regulations were followed before the accident, although the investigator acknowledged there were challenges faced by those on the flight deck in maintaining safety arcs "on multiple spinning aircraft propellers at the same time, especially when two operating aircraft are parked next to each other," according to the Navy Times article, which published Jan. 16.
14 displaced after 2-alarm condo fire in Hilltop area
Virginia Beach / 1 min ago
VBPD chief: Mass shooting independent investigator erred in saying they had no access to shooter's computer


The Santa Clara Community Garden is putting on a free composting workshop this weekend in Eugene.
EUGENE, Ore. -- The Santa Clara Community Garden is putting on a free composting workshop this weekend in Eugene.
Participants will learn more about different composting methods, including hot and cold compost, lasagna, cover crops and soil building with worms.
The event will take place Saturday at 10 a.m. behind St. Matthew's Episcopal Church, 4110 River Road.
You don't need to preregister to participate.


Hello TG community, my clan and I were wondering maybe creating clan vs. clan battles.
I want to talk with seniors of TG clan, but I cant find any TS3 information in forums, can anyone give me IP and Port?
Chumazik from The Opposition Force 4.
Chumazik, first I'd like to welcome you to TacticalGamer!
For a little background information on us, TacticalGamer is actually not a clan, but a community of like minded gamers, open to anyone! We have over 20,000 registered members on our forums, host a multitude of titles and have active players in countless others.
You are more than welcome to hop on our teamspeak server to say hello or join us for some digital action using the information that damonte provided. However, if you're strictly looking to talk to the "big dogs" for BC2 to set up competition, your best bet is to post a thread about it in the BC2 Contact An Admin Forum. That way the admin staff will have an open spot to work out the details and such with you!
Again, welcome to TacticalGamer, and we look forward to seeing you on the battlefield!


text:
Global Hard Seltzer (1.0% -4.9%, 5.0%-6.9%) Market Size, Share & Trends Analysis Report 2021-2028 – ResearchAndMarkets.com
DUBLIN, January 05, 2022–(BUSINESS WIRE)–The "Hard Seltzer Market Size, Share & Trends Analysis Report By ABV Content (1.0% to 4.9%, 5.0% to 6.9%), By Distribution Channel (Off-trade, On-trade), By Region (North America, Europe, ROW), And Segment Forecasts, 2021 – 2028" report has been added to ResearchAndMarkets.com's offering.
The global hard seltzer market size is expected to reach USD 49.4 billion by 2028 and is expected to expand at a CAGR of 31.4% from 2021 to 2028
Shifting consumer preference for low alcohol content beverages especially among millennials and the working-class population is expected to be a key factor contributing to the growth of the market.
Hard seltzers are gaining popularity as low-calorie and low-sugar alternative alcoholic drinks to traditional alcoholic beverages among the health-conscious demographics across the world. Hard seltzer flavors such as citrus and other fruity flavors are gaining rapid traction among consumers. The rising adoption of new flavors among consumers is likely to provide opportunities to the players operating in this market.
For instance, in March 2021 Stewarts Enterprises launched Stewart's Spiked Seltzer, a line of low-calorie hard seltzers in three flavors: Root Beer, Orange Cream, and Black Cherry, to expand in the northeast U.S. Hard seltzer with 5.0% to 6.9% ABV content held the largest segment share in 2020 and is expected to maintain dominance over the forecast period. The high consumption and wide availability of hard seltzer of this category, especially in the North American region, are driving the growth of this segment.
The off-trade segment contributed a majority of the share to become a larger division in the global revenue in 2020. The increasing availability of such products at Walmart, Target, Costco, and Tesco among others has helped in driving the sale of hard seltzer through the off-trade channel. Further, the closure of the on-trade channel due to the outbreak of COVID-19 has also boosted sales through the off-trade channel.
The market is consolidated in the U.S. with a major share occupied by Mark Anthony Brands International and The Boston Beer Company. However, it is fragmented in other regions/countries owing to the presence of a large number of players including Mark Anthony Brands International, Anheuser-Busch InBev, The Coca Cola Company, Diageo plc, Heineken N.V., and Constellation Brands, Inc. among others.
Hard Seltzer Market Report Highlights
The hard seltzer with 1.0% to 4.9% ABV content is projected to register the fastest growth rate over the forecast period owing to increasing demand for low-alcoholic beverages among millennials and Gen Z
The on-trade channel segment is anticipated to register a CAGR of 34.0% from 2021 to 2028 due to the rising demand for it instead of beer and cocktails in pubs and bars
The Rest of the World (RoW) is expected to register the fastest growth during the forecast period. Countries such as China, Australia, New Zealand, India, and UAE among others are expected to see a rapid surge in the consumption of hard seltzer
Chapter 1. Methodology and Scope
2.1. Market Outlook
2.2. ABV Content Outlook
2.3. Distribution Channel Outlook
Chapter 3. Hard Seltzer Market Variables, Trends & Scope
3.1. Market Introduction
3.2. Penetration & Growth Prospect Mapping
3.3. Impact of COVID-19 on the Hard seltzer Market
3.4. Industry Value Chain Analysis
3.5. Market Dynamics
3.6. Business Environment Analysis
3.7. Roadmap of Hard Seltzer Market
3.8. Market Entry Strategies
Chapter 4. Consumer Behavior Analysis
4.1. Demographic Analysis
4.2. Consumer Trends and Preferences
4.3. Factors Affecting Buying Decision
4.4. Consumer Product Adoption
4.5. Observations & Recommendations
Chapter 5. Hard Seltzer Market: ABV Content Estimates & Trend Analysis
5.1. ABV Content Movement Analysis & Market Share, 2020 & 2028
5.2. 1.0% to 4.9%
Chapter 6. Hard Seltzer Market: Distribution Channel Estimates & Trend Analysis
6.1. Distribution Channel Movement Analysis & Market Share, 2020 & 2028
6.2. Off-trade
6.3. On-trade
Chapter 7. Hard Seltzer Market: Regional Estimates & Trend Analysis
7.1. Regional Movement Analysis & Market Share, 2020 & 2028
Chapter 8. Competitive Analysis
8.1. Key global players, recent developments & their impact on the industry
8.2. Key Company/Competition Categorization (Key innovators, Market leaders, Emerging players)
8.3. Vendor Landscape
8.3.1. Key company market share analysis, 2020
Mark Anthony Brands International
Anheuser-Busch InBev
The Coca Cola Company
Heineken N.V.
The Boston Beer Company
Constellation Brands, Inc.
For more information about this report visit https://www.researchandmarkets.com/r/enflt6
New to Investing? Here's Where to Put Your Money
USD/CAD analysis: Reveals new support zone


Rustic Woodworks of Rhinelander WI specializes in staining and refinishing log homes and any wood surface in the Northwoods and U.P. regions. Your cottage home requires special expertise and quality assurance. Contact the best in the business for an honest appraisal and quality Guaranteed.
Give your log home a beautiful interior & exterior that wont' require all the upkeep. We'll give you the very best results for your dollar. Not only will we stain or paint your interior to your exact specifications, we've got the expertise to address chinking & caulking and all your finishing needs.
Protect your log home from the elements and avoid that shabby look by maintaining a strong caulk in your walls. Ensuring that your walls are properly sealed is an excellent way to cut home energy costs and decrease your household's carbon footprint. We do it right the first time for a chink and caulk job that lasts.
For all your wood or log home maintenance and restoration needs, call the areas most trusted company. Contact us with any question & will give you the information and quality service you need to protect your investments and properties for years to Come. Check out our Photos for some of our recent work.
Rustic Woodworks specializes in staining and refinishing log homes in the Northwoods and U.P. regions. Your cottage home requires special expertise and quality assurance.


text:
Family Halloween Thrills on SKY Select
Halloween can mean different things to different people. For the kids, it's a time to have fun, for their imaginations to run wild as they wear different costumes and go out trick-or-treating. For teens and adults, it can be for exploring fears and the darker sides of reality. For many more in the country, it is a time for remembering those who have passed on, honoring their memories when they were alive.
But the family as whole often loves to gather, and spend precious moments with each other, often in comfort while watching fun or thrilling Halloween specials in their big TV screens at home. This October 30 and 31, an entire host of SKY Select channels will air shows and movies that will find their own unique space in the viewers' hearts – whether it be for lighthearted joy or nerve-wracking terror.
The warmest and fondest Halloween memories form during childhood. Among them were Halloween cartoon and movie marathons that can be watched all day. In Boomerang, kids who want to experience the classic antics of Garfield can tune-in to Garfield Special: Bewitched, 10am on October 31. In this hilarious misadventure, Garfield finds himself as a witch's assistant, in his search for a cure to turn Odie back into a dog. Starting 11am, Boomerang will air the Scooby Doo Halloween Movie Marathon where fans can watch Mystery Inc get out of one hijink and into another.
Disney Junior has a halloween special for our youngest kids. By 8:30am on October 31, kids can watch the Jake and the Neverland Pirate's "Stowaway Ghosts/Happy 100th Birthday" episode. Viewers will witness Pirate Mummy's 1000th birthday and how Jake and his friends helped Hook get rid of trickster phantoms.
Movie treats fit for the entire family will be featured in Fox Family Movies. Ghostbusters airs by 9:55pm on October 31. Fans of this classic can watch how Bill Murray, Dan Aykroyd, and Sigourney Weaver handle ghosts and terrors in the most comedic way possible. Ghostbusters II follows at 11:40pm. In this sequel, the Ghostbusters deal with a resurgence of paranormal activity due to the presence of an ectoplasmic river beneath their city.
Fans of grim delights will enjoy the film offerings of Fox Action Movies. On October 30, 10pm, horror afficionados can watch the premier of Wer – a story about a peculiar man blindly charged for committing gruesome murders. A.J. Cook, Sebastian Roche, and Vik Sahay stars in this film about the rebirth of an unexpected legend. The following night, by 10pm, is the premiere of Dark Was the Night. Starring Kevin Durang and Lukas Haas, the story focuses on how the local sheriff faces the demons of his past as he deals with the evils that awoke in the trees.
Halloween movie specials grow even darker with Fox Movies Premium's terrifying selections. In Devil's Due, starring Allison Miller, Zach Gilford, and Sam Anderson, a young couple comes to grips with an unexpected turn of events – a pregnancy after a long and mysterious honeymoon night. The story will unfold starting 10pm on October 30. Action and suspense spills through the TV screen the following night, with the horror flick, The Pyramid. Ashley Hinshaw, James Buckley, and Denis O'Hare stars in this frightful story, where a group of american arheologists are trapped and hunted within a pyramid in the egyptian desert. Movie airs October 31, by 10pm.
Posted by ketchupthelatest at 9:01 AM
Labels: Halloween, SKY Select
SKYcable Subscriber Wins a Subaru Forester in HITS...
Cable TV Made More Affordable with SKYcable Prepai...


text:
Q: Remapping layers in QGIS project to other folders? I created a QGIS project containing several layers which are on my PC. I saved the project to my local drive and then I saved it to the network and copied all the relevent project layers into a folder except the osmap shp files which are on a separate network drive.
I then hunted for a way to remap the QGIS project layers so it points to the network copies and not my local drive.
In AutoCAD this is easy, but I can't find a way to do it in QGIS.
I then tried just deleting the layers from the project and then re-adding them from the new location, but I got a minidump crash every time.
I ended up saving the print composers as templates, exporting the layer styles. Then I created a new project, using the files on the network, and created new print composers from the saved templates.
Is there an easier way to make this project available to other users?
I've seen some info about mapping bad layers, but I couldn't find a dialogue box to do that.
If nothing else, everything on the network will eventually end up on the archive drive and we need to be able to keep projects together.
For example, in CAD if I open a project and someone has moved a file into a new folder, it will tell me that it can't find the external reference. I then open the x-refs window, scroll to the saved path, click browse, then find the file in its new folder and click on it. That saves the changed path.

Based on responses so far, I now know that I need to know how to set a path to relative AND how to remap a path to a different folder.
One response gives a plugin for the latter, so I will try that.
I am close to understanding the former.
The answer seems to be as follows -
Save project. Then use the save button again which creates a project home folder. Use Qpackage to copy the shp files to the new destination. Than open that new project and save to create a new project home folder.
Then use change data source to remap all the layers to the project home folder (as QGIS does NOT save anything as relative at all. It saves all paths as absolute.)

A: You have a great plugin named "ChangeDataSource", doing just that very easily. The only downside is that you can only do one layer at a time.
Works on any layer type, including database layers, raster, wms, wfs, etc.

ChangeDataSource
Right click on layer tree to change single layer datasource of click
  on icon to change datasources globally
The plugin allows to change the datasources of the loaded layers. The
  operation can be performed right clicking on legend items for single
  layer or globally on a summary table by clicking on toolbar plugin
  icon. The plugin takes control of bad layers handling allowing to
  specify valid datasources working on project

See also :

*

*For more layer at a time, see @JGH answer.

*Handling bad layers : Updating file locations in QGIS projects?

ADDITIONAL INFO ON RELATIVE AND ABSOLUTE PATHS
QGIS will like to have all it's data close to its project...

the '.' string means "the folder the .qgs is in.
  the '..' string means "the folder up from where the project qgs is.

example :

*

*if you have a //NETWORK/WORK directory where your qgs is saved (i.e //NETWORK/WORK/myproject.qgs), you can use ./subfolder/mylayer.shp (relative path) to point out to //NETWORK/WORK/subfolder/mylayer.shp (absolute path)  which makes your project movable.

*you can use ../otherfolder/mylayer.shp (relative path) to point out to //NETWORK/otherfolder/mylayer.shp (absolute path).

This way, you'll make your project movable, as long as your data is positionned in the right relative place. You can set this behaviour as default in the project properties (Project Menu).

Réf. Saving project with data source path as relative in QGIS?

A: you can open the qgs project file in your favorite text editor and do a search/replace with the old/new path.

A: JGH's answer is a good one for changing a lot of layer location references, but it needs an update for .qgz project files. You cant' just open a .qgz in a text editor because it's a compressed XML file. For .qgz, you have to

*

*Open the .qgz file with Winzip, 7zip, or a similar tool

*Open the .qgs file stored inside the .qgz file in your text (or XML) editor

*Edit the file system paths, being careful not to break the XML formatting

*Save the edited .qgs file back inside the .qgz file

I just did this very thing, and it took me a couple of extra tries to get the two levels of saving (save the XML, save the compressed .qgz that contains it) right. Your file-compressing/uncompressing program will have its own way of doing this, so I don't think I can provide a universal procedure.
Refer to this answer for more on .qgz v .qgs


text:
Phil Neville's Manchester United downs Man City
A charity football match including tech entrepreneurs and former City star Dennis Tueart raised £40k
BC sportBC north-west
Jonathan Symcox	 1:52pm 12th Jan 2018
The winning side
A charity football match which featured a Manchester United side managed by Phil Neville and North West tech entrepreneurs helped raise £40,000 for Manchester's Factory Youth Zone.
The second Reds V Blues charity football match saw the Reds of Manchester United legend Neville beat the Blues of former Manchester City and England winger Dennis Tueart 3-2 at Altrincham Football Club.
The game was organised by Will Lewis, OBI Property and Chris Davis, chief executive, MoneyPlus Group.
Factory Youth Zone chief executive Richard Marsh said: "A huge thank you to the players, managers, hosts, sponsors and supporters, raising £40k is an amazing achievement and it will undoubtedly make a difference to the young people we work with.
"We aim to encourage these young people to have dreams and aspirations, and to challenge themselves, and us, to achieve their goals.
"The support of Manchester's business community, of which I am consistently overwhelmed by, continues to be vital."
Lewis said: "Factory Youth Zone is a fantastic organisation and I am proud we are able to support them.
"I'd like to thank DWF, Carfinance 247, MoneyPlus Group and Russells Construction for their support this year and all the volunteer players."
The match, which is now an annual fixture, brought together some of the Manchester's best known names in business including tech names Reg and Louis Rix, the founders of CarFinance 24/7, and Steve Oliver, co-founder and group CEO, Music Magpie.
Former Stoke striker Ricardo Fuller was on the scoresheet for United.
The Factory Youth Zone is a charity which provides support for disadvantaged young people from Manchester.
It offers a wide range of activities including sports, arts, youth work sessions and specialist workshops with the aim of improving the lives of local young people in one of the most deprived areas of the UK.
3ecruit sees export boom after market expansion
12th, Apr
The tech recruitment specialist has moved into new markets including…
Fighter jet technology to boost British equestrian teams
17th, Jan
BAE Systems' partnership with UK Sport to support elite-level horses…
5G technology will 'take over the world'
9th, Jul
Chris Costello, director of tech store Sync, says 5G will…


text:
Q: creating a 9path image I tried to create a 9 path drawable for a chat bubble

I want the image to extend vertically and have the little arrow unchanged.
I followed a few tutorials and added patches to the image then saved it as bubble.9.png but it doesn't work properly in my app. here is a screen shot

What am I doing wrong?

A: 9-patch drawable needs both horizontal and vertical patches. Your bubble is missing markers on top and bottom lines of image.
Here is quick sample of working 9-patch:

More info can be found in official documentation http://developer.android.com/reference/android/graphics/NinePatch.html
You may also try to use official tool for editing 9-patches http://developer.android.com/guide/developing/tools/draw9patch.html . It has live preview and it can automatically convert normal image to 9-patch by adding border pixels. You will only need to mark necessary content and stretch areas.


Ruby is one of the easier programming languages one can learn. One who is able to master Ruby programming skills can actually look forward to excellent career opportunities. A brief training course Ruby 101 Training in Melbourne will be a perfect stepping stone for the web and mobile app programmer to launch himself into the high-demand bracket of programmers.
give an option to choose between weekday and weekend batches.
The training Institute also extends personalized services like access to course Material, resources in the library etc., by which the candidate can understand how advanced Ruby can be used. During the Ruby 101 Course in Melbourne, the candidate gets exposure to the basics of Ruby through a 24-hour program, where he has the flexibility to choose 2 hours or 4 hours a day, and can learn through the instructor-led interactive Ruby 101 Training in Melbourne. He can create reusable and robust code by applying designing best practices and also have access to exercise Material, courseware and sample programs.
Firstly, the participant gets to refine his skills in Ruby on his own, and secondly, he has expert guidance coming from the Tutor, who helps him implement his web program through live industry-level projects. Thirdly, at the end of the Ruby 101 Training Course in Melbourne, the candidate is awarded a course completion certificate, which is an excellent credential to possess in the industry, for benefitting the career of the programmer.


Serpina controls hypertension, anxiety and tension.
Serpina causes depletion of peripheral catecholamine (noradrenaline) stores, which results in a reduction of blood pressure. Serpina decreases the adrenergic tone and controls anxiety, and is therefore beneficial in the treatment of anxiety disorders.
Use Serpina as directed by your doctor.
Take 1 capsule twice a day after meals.
If you miss a dose of Serpina take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.
Ask your health care provider any questions you may have about how to use Serpina.
Store Serpina at 77 degrees F (25 degrees C). Store away from heat, moisture, and light. Do not store in the bathroom. Keep Serpina out of the reach of children and away from pets.
you are allergic to any ingredient in Serpina.
Serpina is not known to have any side effects if taken as per the prescribed dosage.


Coving Fitter Oxford Oxfordshire: Should you be planning to brighten up your house in Oxford, Oxfordshire, with the addition of some attractive looking coving round the ceilings of rooms, then you will be looking to find a coving fitter to complete the task for you.
The installation of coving around the ceilings of rooms in our houses is a fad that has gone into and out of fashion through the years. However, coving can be an attractive addition for virtually any room or space and is worth taking into consideration if you would like to improve the decoration of your property in Oxford.
Indeed, you can purchase pre-cut products or specially made corner pieces to aid with those complex angles. So you might believe that it's possible to take on this project by yourself, although to be candid, it can be a bit beyond the ability of the typical do-it-yourselfer. Thereby, locating an expert coving fitter in Oxford may very well be the best route if you want to make certain the job is done properly.
Coving - What is It? - Coving can be used to round the corners where ceilings join walls in a home, and is a specially moulded product which can be manufactured using different types of materials, for example polyethylene, PVC, MDF, plaster, high density polystyrene, solid wood, polyurethane, gyproc, duropolymer and even plastic. Whilst coving is usually employed inside, it may also be used outside the house, for example to enhance the look of eaves. Coving designs can range from very simple quadrant versions to extremely complex designs. Coving usually comes in straight lengths of 2-3m with several ranges coming with pre-cut angle and corner sets, making the life of your coving fitter, a bit easier.
If you will be intending to shop for coving products in the Oxford area, you will need to head on down to the nearest DIY centre, several of which ought to have a choice in store, whilst for specialist coving products, for example solid wood coving you might need to enquire at a local Oxford joinery works or workshop. Virtually all of the major builders merchants and DIY retailers have some coving in stock, therefore if you have a Jewson, Homebase, Wickes, Travis Perkins, Screwfix or B&Q in your region, you should be easily able to purchase just what you need.
With certain sorts of coving it is even a possibility to fit LED lights inside the coving to achieve a spectacular effect and give that real WOW factor to the rooms. You will obviously need the assistance of an electrical contractor for this kind of work.
When trying to identify a specialist coving fitter in Oxford, Oxfordshire, you could perhaps look at heading to the tradesmens portal, Rated People, where you will need to go to the "Plasterers" section. Plasterers tend to be the traditional tradesmen to speak to putting in coving, though needless to say, if you're going to fit timber coving, then contacting a joiner in Oxford may perhaps be a better option. You might likewise try your neighbourhood handyman or odd job man, who may be happy to accept a coving project in Oxford.
If you carry out a thorough investigation you ought to be able to get Victorian style coving and cornices in Oxford, duropolymer coving installation in Oxford, a cornice fitter in Oxford, a wood coving fitter in Oxford, coving and decorative mouldings fitted in Oxford, a ceiling coving fitter in Oxford, coving installed in your kitchen in Oxford, a plaster coving fitter in Oxford, cornices and ceiling roses fitted in Oxford, coving fitted in your lounge in Oxford, polyethylene coving installation in Oxford, covings and cornices fitted in Oxford, a Victorian coving fitter in Oxford, a plaster coving fitter in Oxford, coving installed in your bedroom in Oxford, a cheap coving fitter in Oxford, a PVC coving fitter in Oxford, an expert coving fitter in Oxford, a plaster coving fitter in Oxford, decorative coving installed in Oxford, a gyproc coving fitter in Oxford, fancy coving installed in Oxford, affordable coving installation in Oxford, picture and dado rails fitted in Oxford and get other ornamental mouldings installed in Oxford.
While tracking down a coving fitter in Oxford you may also be in need of an odd job man in Oxford, an artexer in Oxford, decorators in Oxford, builders in Oxford, a plasterer in Oxford, carpenters in Oxford, an electrician in Oxford and coving products in Oxford, Oxfordshire.